[儿童非霍奇金淋巴瘤的治疗结果：KYCCSG NHL - 89、96]

[Treatment outcome of non-Hodgkin lymphoma in childhood: KYCCSG NHL-89, 96].

作者信息

Fukano Reiji, Suminoe Aiko, Matsuzaki Akinobu, Inada Hiroko, Nagatoshi Yoshihisa, Ishii Eiichi, Nakayama Hideki, Kawakami Kiyoshi, Moritake Hiroshi, Yanai Fumio, Itonaga Nobuyoshi, Suenobu Soichi, Kikuchi Masahiro, Okamura Jun, Kawano Yoshifumi

机构信息

Yamaguchi University, Japan.

出版信息

Rinsho Ketsueki. 2012 Nov;53(11):1898-905.

PMID:23257670

Abstract

Two consecutive treatment protocols, NHL-89 and NHL-96, for pediatric diffuse large cell lymphoma (DLC) and lymphoblastic lymphoma (LBL) were conducted between March 1989 and December 2004 by Kyushu-Yamaguchi Children's Cancer Study Group. Forty-two patients (DLC: 15, LBL: 27) and 34 patients (DLC: 8, LBL: 26) were enrolled in NHL-89 and NHL-96, respectively. DLC patients received induction therapy of high-dose methotrexate (MTX) followed by repeated administration of intermediate MTX. LBL patients received a 4-drug induction followed by intensification, consolidation with cranial radiotherapy (15 to 24Gy), and maintenance. The maintenance phase consisted of multiple drug treatment; including prednisolone, vincristine, cyclophosphamide, and 6-mercaptopurine. With a median follow-up of 150 months for NHL-89 and 90.5 months for NHL-96, the estimated event-free survival at 5 years are 76.2±6.6% and 67.7±8.0%, respectively. Both studies improved the prognosis of DLC and LBL over our previous study of NHL-858.

摘要

1989年3月至2004年12月期间，九州-山口儿童癌症研究组实施了针对儿童弥漫性大细胞淋巴瘤（DLC）和淋巴细胞性淋巴瘤（LBL）的两个连续治疗方案，即NHL-89和NHL-96。分别有42例患者（DLC：15例，LBL：27例）和34例患者（DLC：8例，LBL：26例）纳入NHL-89和NHL-96研究。DLC患者接受大剂量甲氨蝶呤（MTX）诱导治疗，随后重复给予中等剂量MTX。LBL患者接受四联诱导治疗，随后进行强化治疗、采用颅脑放疗（15至24Gy）巩固治疗以及维持治疗。维持阶段采用多种药物治疗，包括泼尼松龙、长春新碱、环磷酰胺和6-巯基嘌呤。NHL-89的中位随访时间为150个月，NHL-96为90.5个月，5年时的估计无事件生存率分别为76.2±6.6%和67.7±8.0%。与我们之前对NHL-858的研究相比，这两项研究均改善了DLC和LBL的预后。